UBS Group’s Pfizer PFE Stock Holding History

UBS Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$494M	Buy	17,609,150 +811,135	+5%	+$21.6M	0.07%	272
2025 Q4	$418M	Sell	16,798,015 -4,998,601	-23%	-$126M	0.07%	272
2025 Q3	$555M	Sell	21,796,616 -2,021,043	-8%	-$49.9M	0.09%	214
2025 Q2	$577M	Sell	23,817,659 -1,232	-0%	-$28.7K	0.1%	196
2025 Q1	$604M	Sell	23,818,891 -3,220,014	-12%	-$84.3M	0.11%	178
2024 Q4	$717M	Buy	27,038,905 +3,795,376	+16%	+$103M	0.13%	146
2024 Q3	$673M	Buy	23,243,529 +3,292,353	+17%	+$96M	0.15%	128
2024 Q2	$558M	Buy	19,951,176 +3,334,517	+20%	+$91.8M	0.14%	137
2024 Q1	$461M	Buy	16,616,659 +1,560,892	+10%	+$43.3M	0.11%	164
2023 Q4	$433M	Buy	15,055,767 +338,325	+2%	+$10.2M	0.13%	159
2023 Q3	$488M	Sell	14,717,442 -1,749,197	-11%	-$61.9M	0.17%	120
2023 Q2	$604M	Sell	16,466,639 -2,153,286	-12%	-$83.8M	0.2%	105
2023 Q1	$760M	Buy	18,619,925 +726,356	+4%	+$31.4M	0.28%	71
2022 Q4	$917M	Buy	17,893,569 +2,991,764	+20%	+$143M	0.34%	55
2022 Q3	$652M	Sell	14,901,805 -2,177,923	-13%	-$106M	0.29%	69
2022 Q2	$895M	Buy	17,079,728 +294,801	+2%	+$15M	0.37%	48
2022 Q1	$869M	Sell	16,784,927 -708,211	-4%	-$36.7M	0.29%	70
2021 Q4	$1.03B	Buy	17,493,138 +200,653	+1%	+$9.94M	0.3%	62
2021 Q3	$744M	Buy	17,292,485 +251,439	+1%	+$11.1M	0.23%	96
2021 Q2	$667M	Sell	17,041,046 -1,742,222	-9%	-$67.8M	0.22%	102
2021 Q1	$681M	Sell	18,783,268 -1,965,358	-9%	-$69.8M	0.23%	101
2020 Q4	$764M	Buy	20,748,626 +1,837,833	+10%	+$67.4M	0.26%	80
2020 Q3	$658M	Buy	18,910,793 +1,735,330	+10%	+$60.8M	0.25%	95
2020 Q2	$533M	Sell	17,175,463 -890,884	-5%	-$30.3M	0.23%	105
2020 Q1	$559M	Sell	18,066,347 -4,048,740	-18%	-$138M	0.26%	84
2019 Q4	$822M	Sell	22,115,087 -2,036,083	-8%	-$72.5M	0.29%	71
2019 Q3	$823M	Sell	24,151,170 -148,165	-0.6%	-$5.39M	0.32%	66
2019 Q2	$999M	Buy	24,299,335 +4,102,112	+20%	+$163M	0.38%	54
2019 Q1	$814M	Sell	20,197,223 -1,824,192	-8%	-$73.1M	0.34%	62
2018 Q4	$912M	Sell	22,021,415 -119,143	-0.5%	-$4.95M	0.41%	43
2018 Q3	$926M	Sell	22,140,558 -977,619	-4%	-$37.6M	0.37%	55
2018 Q2	$796M	Buy	23,118,177 +1,071,890	+5%	+$36.6M	0.34%	55
2018 Q1	$742M	Sell	22,046,287 -1,046,968	-5%	-$36M	0.32%	65
2017 Q4	$794M	Buy	23,093,255 +1,397,013	+6%	+$47.6M	0.33%	63
2017 Q3	$735M	Buy	21,696,242 +269,744	+1%	+$8.67M	0.34%	56
2017 Q2	$683M	Buy	21,426,498 +539,323	+3%	+$17M	0.35%	59
2017 Q1	$678M	Buy	20,887,175 +2,650,923	+15%	+$83.6M	0.37%	50
2016 Q4	$562M	Buy	18,236,252 +722,947	+4%	+$22.1M	0.31%	59
2016 Q3	$563M	Buy	17,513,305 +1,609,922	+10%	+$53.8M	0.34%	57
2016 Q2	$531M	Sell	15,903,383 -367,314	-2%	-$11.7M	0.33%	51
2016 Q1	$458M	Sell	16,270,697 -2,639,643	-14%	-$75.4M	0.31%	57
2015 Q4	$579M	Buy	18,910,340 +2,194,106	+13%	+$69M	0.38%	40
2015 Q3	$498M	Sell	16,716,234 -1,130,406	-6%	-$36.2M	0.35%	44
2015 Q2	$568M	Buy	17,846,640 +1,345,885	+8%	+$43.9M	0.38%	36
2015 Q1	$545M	Sell	16,500,755 -6,282,943	-28%	-$200M	0.38%	37
2014 Q4	$673M	Buy	+22,783,698	New	+$653M	0.47%	24

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

UBS Group's PFE Position: Q1 2026 in Review

UBS Group increased its Pfizer (PFE) stake by 4.8% in Q1 2026, buying an estimated $21.6M and bringing the position to 17,609,150 shares worth $494M. The position accounts for 0.07% of the portfolio, ranked #272.

UBS Group first reported a position in PFE in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.03B in Q4 2021. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

UBS Group held 17,609,150 shares of Pfizer worth $494M as of Q1 2026.
UBS Group bought 811,135 Pfizer shares in Q1 2026, an estimated $21.6M.
Pfizer made up 0.07% of UBS Group's portfolio in Q1 2026, its #272 holding.
UBS Group first reported a position in Pfizer in Q4 2014 and has held it in 46 quarters since.
UBS Group's Pfizer position peaked at $1.03B in Q4 2021.
2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.